Skip to main content
Journal cover image

Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.

Publication ,  Journal Article
Barber, EL; Dusetzina, SB; Stitzenberg, KB; Rossi, EC; Gehrig, PA; Boggess, JF; Garrett, JM
Published in: Gynecol Oncol
June 2017

OBJECTIVE: To estimate variation in the use of neoadjuvant chemotherapy by high volume hospitals and to determine the association between hospital utilization of neoadjuvant chemotherapy and survival. METHODS: We identified incident cases of stage IIIC or IV epithelial ovarian cancer in the National Cancer Database from 2006 to 2012. Inclusion criteria were treatment at a high volume hospital (>20 cases/year) and treatment with both chemotherapy and surgery. A logistic regression model was used to predict receipt of neoadjuvant chemotherapy based on case-mix predictors (age, comorbidities, stage etc). Hospitals were categorized by the observed-to-expected ratio for neoadjuvant chemotherapy use as low, average, or high utilization hospitals. Survival analysis was performed. RESULTS: We identified 11,574 patients treated at 55 high volume hospitals. Neoadjuvant chemotherapy was used for 21.6% (n=2494) of patients and use varied widely by hospital, from 5%-55%. High utilization hospitals (n=1910, 10 hospitals) had a median neoadjuvant chemotherapy rate of 39% (range 23-55%), while low utilization hospitals (n=2671, 14 hospitals) had a median rate of 10% (range 5-17%). For all ovarian cancer patients adjusting for clinical and socio-demographic factors, treatment at a hospital with average or high neoadjuvant chemotherapy utilization was associated with a decreased rate of death compared to treatment at a low utilization hospital (HR 0.90 95% CI 0.83-0.97 and HR 0.85 95% CI 0.75-0.95). CONCLUSIONS: Wide variation exists in the utilization of neoadjuvant chemotherapy to treat stage IIIC and IV epithelial ovarian cancer even among high volume hospitals. Patients treated at hospitals with low rates of neoadjuvant chemotherapy utilization experience decreased survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

June 2017

Volume

145

Issue

3

Start / End Page

500 / 507

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged
  • Logistic Models
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Barber, E. L., Dusetzina, S. B., Stitzenberg, K. B., Rossi, E. C., Gehrig, P. A., Boggess, J. F., & Garrett, J. M. (2017). Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. Gynecol Oncol, 145(3), 500–507. https://doi.org/10.1016/j.ygyno.2017.03.014
Barber, Emma L., Stacie B. Dusetzina, Karyn B. Stitzenberg, Emma C. Rossi, Paola A. Gehrig, John F. Boggess, and Joanne M. Garrett. “Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.Gynecol Oncol 145, no. 3 (June 2017): 500–507. https://doi.org/10.1016/j.ygyno.2017.03.014.
Barber EL, Dusetzina SB, Stitzenberg KB, Rossi EC, Gehrig PA, Boggess JF, et al. Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. Gynecol Oncol. 2017 Jun;145(3):500–7.
Barber, Emma L., et al. “Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.Gynecol Oncol, vol. 145, no. 3, June 2017, pp. 500–07. Pubmed, doi:10.1016/j.ygyno.2017.03.014.
Barber EL, Dusetzina SB, Stitzenberg KB, Rossi EC, Gehrig PA, Boggess JF, Garrett JM. Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. Gynecol Oncol. 2017 Jun;145(3):500–507.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

June 2017

Volume

145

Issue

3

Start / End Page

500 / 507

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged
  • Logistic Models
  • Humans